{"id":"https://openalex.org/W1503352903","doi":"https://doi.org/10.1111/dom.12261","title":"Modeling effects of SGLT \u20102 inhibitor dapagliflozin treatment versus standard diabetes therapy on cardiovascular and microvascular outcomes","display_name":"Modeling effects of SGLT \u20102 inhibitor dapagliflozin treatment versus standard diabetes therapy on cardiovascular and microvascular outcomes","alternate_titles":[],"publication_year":2014,"publication_date":"2014-02-19","ids":{"openalex":"https://openalex.org/W1503352903","doi":"https://doi.org/10.1111/dom.12261","mag":"1503352903","pmid":"https://pubmed.ncbi.nlm.nih.gov/24443793"},"language":"en","primary_location":{"id":"doi:10.1111/dom.12261","doi":"https://doi.org/10.1111/dom.12261","is_oa":false,"landing_page_url":"https://doi.org/10.1111/dom.12261","pdf_url":null,"source":{"id":"https://openalex.org/S148394532","display_name":"Diabetes Obesity and Metabolism","issn_l":"1462-8902","issn":["1462-8902","1463-1326"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes, Obesity and Metabolism","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W1503352903"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5080450831","display_name":"Julia Dziuba","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"J. Dziuba","raw_affiliation_strings":["Department of Science, Archimedes, Inc. San Francisco CA USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Science, Archimedes, Inc. San Francisco CA USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5030781214","display_name":"Peter Alperin","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"P. Alperin","raw_affiliation_strings":["Department of Science, Archimedes, Inc. San Francisco CA USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Science, Archimedes, Inc. San Francisco CA USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5074091536","display_name":"Jill Racketa","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"J. Racketa","raw_affiliation_strings":["Global Medicines Development, Astra\u2010Zeneca Wilmington DE USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Global Medicines Development, Astra\u2010Zeneca Wilmington DE USA","institution_ids":["https://openalex.org/I4210150756"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5075400058","display_name":"Uchenna H. Iloeje","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"U. Iloeje","raw_affiliation_strings":["Research and Development, Bristol\u2010Myers Squibb New York NY USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Research and Development, Bristol\u2010Myers Squibb New York NY USA","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111600646","display_name":"Devesh Goswami","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"D. Goswami","raw_affiliation_strings":["Department of Science, Archimedes, Inc. San Francisco CA USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Science, Archimedes, Inc. San Francisco CA USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5050249929","display_name":"Elise Hardy","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"E. Hardy","raw_affiliation_strings":["Global Medicines Development, Astra\u2010Zeneca Wilmington DE USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Global Medicines Development, Astra\u2010Zeneca Wilmington DE USA","institution_ids":["https://openalex.org/I4210150756"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5066241810","display_name":"Itay Perlstein","orcid":"https://orcid.org/0000-0001-8700-3957","observed_orcids":["https://orcid.org/0000-0001-8700-3957"]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"I. Perlstein","raw_affiliation_strings":["Department of Exploratory Clinical & Translational Research, Bristol-Myers Squibb, New York, NY, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Exploratory Clinical & Translational Research, Bristol-Myers Squibb, New York, NY, USA","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5079282100","display_name":"Helene L. Grossman","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"H. L. Grossman","raw_affiliation_strings":["Department of Science, Archimedes, Inc. San Francisco CA USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Science, Archimedes, Inc. San Francisco CA USA","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5076075120","display_name":"Marc Maurice Cohen","orcid":"https://orcid.org/0000-0002-5876-6565","observed_orcids":["https://orcid.org/0000-0002-5876-6565"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"M. Cohen","raw_affiliation_strings":["Department of Science, Archimedes, Inc. San Francisco CA USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Science, Archimedes, Inc. San Francisco CA USA","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5111600646"],"corresponding_institution_ids":[],"apc_list":{"value":5380,"currency":"USD","value_usd":5380},"apc_paid":null,"fwci":8.9086,"has_fulltext":false,"cited_by_count":107,"reviewed_by_count":0,"citation_normalized_percentile":{"value":0.98581616,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":96,"max":100},"biblio":{"volume":"16","issue":"7","first_page":"628","last_page":"635"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10198","display_name":"Heart Failure Treatment and Management","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/dapagliflozin","display_name":"dapagliflozin","score":1.0},{"id":"https://openalex.org/keywords/sglt2-inhibitors","display_name":"SGLT2 inhibitors","score":0.9800000190734863},{"id":"https://openalex.org/keywords/type-2-diabetes","display_name":"type 2 diabetes","score":0.9990000128746033},{"id":"https://openalex.org/keywords/cardiovascular-outcomes","display_name":"cardiovascular outcomes","score":0.9810000061988831},{"id":"https://openalex.org/keywords/microvascular-complications","display_name":"microvascular complications","score":0.9860000014305115},{"id":"https://openalex.org/keywords/computer-simulation","display_name":"computer simulation","score":0.5080000162124634},{"id":"https://openalex.org/keywords/metformin","display_name":"metformin","score":0.7179999947547913},{"id":"https://openalex.org/keywords/sulfonylureas","display_name":"sulfonylureas","score":0.9490000009536743},{"id":"https://openalex.org/keywords/thiazolidinediones","display_name":"thiazolidinediones","score":0.9980000257492065},{"id":"https://openalex.org/keywords/myocardial-infarction","display_name":"myocardial infarction","score":0.9150000214576721},{"id":"https://openalex.org/keywords/stroke","display_name":"stroke","score":0.9829999804496765},{"id":"https://openalex.org/keywords/end-stage-renal-disease","display_name":"end-stage renal disease","score":0.9169999957084656},{"id":"https://openalex.org/keywords/foot-amputation","display_name":"foot amputation","score":0.8500000238418579},{"id":"https://openalex.org/keywords/diabetic-retinopathy","display_name":"diabetic retinopathy","score":0.9860000014305115},{"id":"https://openalex.org/keywords/all-cause-mortality","display_name":"all-cause mortality","score":0.8240000009536743}],"concepts":[{"id":"https://openalex.org/C2777422806","wikidata":"https://www.wikidata.org/wiki/Q409898","display_name":"Dapagliflozin","level":4,"score":0.961664617061615},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9261555671691895},{"id":"https://openalex.org/C2780323712","wikidata":"https://www.wikidata.org/wiki/Q19484","display_name":"Metformin","level":3,"score":0.7581015825271606},{"id":"https://openalex.org/C2777180221","wikidata":"https://www.wikidata.org/wiki/Q3025883","display_name":"Type 2 diabetes","level":3,"score":0.6659337282180786},{"id":"https://openalex.org/C555293320","wikidata":"https://www.wikidata.org/wiki/Q12206","display_name":"Diabetes mellitus","level":2,"score":0.5826644897460938},{"id":"https://openalex.org/C2777538456","wikidata":"https://www.wikidata.org/wiki/Q311213","display_name":"Glycated hemoglobin","level":4,"score":0.5570228099822998},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5292417407035828},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.5106883645057678},{"id":"https://openalex.org/C2776923340","wikidata":"https://www.wikidata.org/wiki/Q1393556","display_name":"Thiazolidinedione","level":4,"score":0.4523315727710724},{"id":"https://openalex.org/C2779306644","wikidata":"https://www.wikidata.org/wiki/Q2002370","display_name":"Insulin","level":2,"score":0.41548240184783936},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.3818483352661133},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.36355265974998474},{"id":"https://openalex.org/C99454951","wikidata":"https://www.wikidata.org/wiki/Q932068","display_name":"Environmental health","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000077203","descriptor_name":"Sodium-Glucose Transporter 2 Inhibitors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D000671","descriptor_name":"Amputation, Surgical","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001559","descriptor_name":"Benzhydryl Compounds","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D001786","descriptor_name":"Blood Glucose","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D001794","descriptor_name":"Blood Pressure","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D001835","descriptor_name":"Body Weight","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D002318","descriptor_name":"Cardiovascular Diseases","qualifier_ui":"Q000209","qualifier_name":"etiology","is_major_topic":false},{"descriptor_ui":"D002318","descriptor_name":"Cardiovascular Diseases","qualifier_ui":"Q000503","qualifier_name":"physiopathology","is_major_topic":false},{"descriptor_ui":"D002318","descriptor_name":"Cardiovascular Diseases","qualifier_ui":"Q000517","qualifier_name":"prevention & control","is_major_topic":true},{"descriptor_ui":"D003924","descriptor_name":"Diabetes Mellitus, Type 2","qualifier_ui":"Q000150","qualifier_name":"complications","is_major_topic":false},{"descriptor_ui":"D003924","descriptor_name":"Diabetes Mellitus, Type 2","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D003924","descriptor_name":"Diabetes Mellitus, Type 2","qualifier_ui":"Q000503","qualifier_name":"physiopathology","is_major_topic":false},{"descriptor_ui":"D003925","descriptor_name":"Diabetic Angiopathies","qualifier_ui":"Q000209","qualifier_name":"etiology","is_major_topic":false},{"descriptor_ui":"D003925","descriptor_name":"Diabetic Angiopathies","qualifier_ui":"Q000503","qualifier_name":"physiopathology","is_major_topic":false},{"descriptor_ui":"D003925","descriptor_name":"Diabetic Angiopathies","qualifier_ui":"Q000517","qualifier_name":"prevention & control","is_major_topic":true},{"descriptor_ui":"D003930","descriptor_name":"Diabetic Retinopathy","qualifier_ui":"Q000517","qualifier_name":"prevention & control","is_major_topic":false},{"descriptor_ui":"D005960","descriptor_name":"Glucosides","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D006442","descriptor_name":"Glycated Hemoglobin","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007004","descriptor_name":"Hypoglycemic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D007676","descriptor_name":"Kidney Failure, Chronic","qualifier_ui":"Q000517","qualifier_name":"prevention & control","is_major_topic":false},{"descriptor_ui":"D008687","descriptor_name":"Metformin","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D008833","descriptor_name":"Microcirculation","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009203","descriptor_name":"Myocardial Infarction","qualifier_ui":"Q000517","qualifier_name":"prevention & control","is_major_topic":false},{"descriptor_ui":"D009749","descriptor_name":"Nutrition Surveys","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013453","descriptor_name":"Sulfonylurea Compounds","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D014527","descriptor_name":"Uric Acid","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D015994","descriptor_name":"Incidence","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018450","descriptor_name":"Disease Progression","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D020521","descriptor_name":"Stroke","qualifier_ui":"Q000517","qualifier_name":"prevention & control","is_major_topic":false},{"descriptor_ui":"D045162","descriptor_name":"Thiazolidinediones","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1111/dom.12261","doi":"https://doi.org/10.1111/dom.12261","is_oa":false,"landing_page_url":"https://doi.org/10.1111/dom.12261","pdf_url":null,"source":{"id":"https://openalex.org/S148394532","display_name":"Diabetes Obesity and Metabolism","issn_l":"1462-8902","issn":["1462-8902","1463-1326"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes, Obesity and Metabolism","raw_type":"journal-article"},{"id":"pmid:24443793","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/24443793","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes, obesity & metabolism","raw_type":"Comparative Study"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320307115","display_name":"Bristol-Myers Squibb","ror":"https://ror.org/00gtmwv55"},{"id":"https://openalex.org/F4320307770","display_name":"AstraZeneca","ror":"https://ror.org/04r9x1a08"}],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":31,"referenced_works":["https://openalex.org/W99459258","https://openalex.org/W336577452","https://openalex.org/W1551875034","https://openalex.org/W1773900241","https://openalex.org/W1971574914","https://openalex.org/W1973240292","https://openalex.org/W2000166571","https://openalex.org/W2002033855","https://openalex.org/W2008443217","https://openalex.org/W2017846084","https://openalex.org/W2024819549","https://openalex.org/W2026480246","https://openalex.org/W2029615800","https://openalex.org/W2034870095","https://openalex.org/W2066843609","https://openalex.org/W2069478329","https://openalex.org/W2082279418","https://openalex.org/W2093707453","https://openalex.org/W2108479359","https://openalex.org/W2111829994","https://openalex.org/W2122077393","https://openalex.org/W2123984464","https://openalex.org/W2132895884","https://openalex.org/W2142006483","https://openalex.org/W2144125787","https://openalex.org/W2151159668","https://openalex.org/W2167984652","https://openalex.org/W2170197815","https://openalex.org/W2171646682","https://openalex.org/W2172193326","https://openalex.org/W4213289640"],"related_works":["https://openalex.org/W3047275959","https://openalex.org/W2973616972","https://openalex.org/W2910145779","https://openalex.org/W2938413915","https://openalex.org/W2614119897","https://openalex.org/W2972424965","https://openalex.org/W3092096274","https://openalex.org/W2076506641","https://openalex.org/W2589252933","https://openalex.org/W2979889868"],"abstract_inverted_index":{"AIMS:":[0],"Dapagliflozin,":[1],"a":[2,67,81,101,194],"sodium-glucose":[3],"cotransporter":[4],"2":[5,83],"(SGLT-2)":[6],"inhibitor,":[7],"has":[8],"been":[9],"shown":[10],"to":[11,40,52,79,130,202,261,268],"lower":[12],"glycated":[13],"hemoglobin":[14],"(HbA1c),":[15],"weight,":[16],"blood":[17],"pressure":[18],"and":[19,46,74,92,152,164,189,216,223,226,239,245,273],"serum":[20],"uric":[21],"acid":[22],"in":[23,128,173,206,229],"clinical":[24,182],"trials.":[25],"Plasma":[26],"lipids":[27],"were":[28,177,200],"also":[29],"evaluated":[30],"as":[31],"exploratory":[32],"variables.":[33],"The":[34,64],"goal":[35],"of":[36,49,55,70,115,147,171,209,219,232,242,256],"this":[37],"study":[38],"was":[39,77,121,136],"estimate":[41],"the":[42,53,113,116,145,207,230,254,271],"long-term":[43],"cardiovascular":[44],"(CV)":[45],"microvascular":[47,190,274],"outcomes":[48],"dapagliflozin":[50,124,199,260],"added":[51],"standard":[54],"care":[56],"(SOC)":[57],"versus":[58],"SOC":[59,133,135],"using":[60],"simulation":[61,257],"methodology.":[62],"METHODS:":[63],"Archimedes":[65],"Model,":[66],"validated":[68],"model":[69,80],"human":[71],"physiology,":[72],"diseases":[73],"healthcare":[75],"systems,":[76],"used":[78],"type":[82],"diabetes":[84],"mellitus":[85],"(T2DM)":[86],"population":[87],"derived":[88,178],"from":[89,179],"National":[90],"Health":[91],"Nutrition":[93],"Examination":[94],"Survey":[95],"(NHANES)":[96],"with":[97,132,167,250,277],"HbA1c":[98],"7-10%,":[99],"taking":[100],"single":[102],"oral":[103],"antidiabetic":[104],"agent":[105],"[metformin,":[106],"sulfonylureas":[107],"SU":[108],"or":[109],"thiazolidinedione":[110],"(TZD)]":[111],"at":[112],"beginning":[114],"trial.":[117],"A":[118],"20-year":[119,195],"trial":[120,183],"simulated":[122],"comparing":[123],"10":[125],"mg,":[126],"given":[127],"addition":[129],"SOC,":[131],"alone.":[134],"based":[137],"on":[138,198],"American":[139],"Diabetes":[140,148],"Association":[141,143],"(ADA)/European":[142],"for":[144],"Study":[146],"(EASD)":[149],"2012":[150],"guidelines":[151],"included":[153,187],"diet,":[154],"metformin,":[155],"SU,":[156],"TZD,":[157],"dipeptidyl":[158],"peptidase-4":[159],"(DPP-4),":[160],"glucagon-like":[161],"peptide-1":[162],"(GLP-1),":[163],"insulin":[165],"therapies,":[166],"usage":[168],"levels":[169],"reflective":[170],"those":[172],"NHANES.":[174],"Dapagliflozin":[175],"effects":[176],"phase":[180],"3":[181],"results.":[184],"End":[185],"points":[186],"CV":[188,214,272],"outcomes.":[191],"RESULTS:":[192],"Over":[193],"period,":[196],"patients":[197],"projected":[201,267],"experience":[203],"relative":[204,227],"reductions":[205,228],"incidence":[208,231],"myocardial":[210],"infarction":[211],"(MI),":[212],"stroke,":[213],"death,":[215],"all-cause":[217],"death":[218],"13.8,":[220],"9.1,":[221],"9.6":[222],"5.0%,":[224],"respectively,":[225,247],"end-stage":[233],"renal":[234],"disease":[235],"(ESRD),":[236],"foot":[237],"amputation,":[238],"diabetic":[240],"retinopathy":[241],"18.7,":[243],"13.0":[244],"9.8%,":[246],"when":[248],"compared":[249],"SOC.":[251],"CONCLUSIONS:":[252],"On":[253],"basis":[255],"results,":[258],"adding":[259],"currently":[262],"available":[263],"treatment":[264],"options":[265],"is":[266],"further":[269],"decrease":[270],"complications":[275],"associated":[276],"T2DM.":[278]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W1503352903","counts_by_year":[{"year":2025,"cited_by_count":4},{"year":2024,"cited_by_count":5},{"year":2023,"cited_by_count":6},{"year":2022,"cited_by_count":11},{"year":2021,"cited_by_count":5},{"year":2020,"cited_by_count":6},{"year":2019,"cited_by_count":9},{"year":2018,"cited_by_count":14},{"year":2017,"cited_by_count":8},{"year":2016,"cited_by_count":24},{"year":2015,"cited_by_count":7},{"year":2014,"cited_by_count":8}],"updated_date":"2026-11-21T10:27:49.728292","created_date":"2016-06-24T00:00:00"}
